Aurobindo Pharma Limited has informed the Exchange about General Updates
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.5 pts more than Nifty Midcap 150 and 2.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Aurobindo Pharma's wholly owned subsidiary Apitoria Pharma has received a Voluntary Action Indicated (VAI) classification from the US FDA for its Unit-V API manufacturing facility in Pashamylaram, Telangana. The facility was inspected from December 1 to December 12, 2025, and was initially issued a Form 483 with 3 observations. After review, the US FDA issued an Establishment Inspection Report (EIR) classifying the unit as VAI, meaning the inspection is now closed with no mandatory corrective action required. VAI is one of the best possible outcomes from a US FDA inspection, indicating that any issues found do not require regulatory action.
Positive for shareholders — the VAI classification removes regulatory uncertainty around the API facility and allows uninterrupted production and exports to the US market, which is Aurobindo's largest revenue geography. This should ease concerns over compliance risks at the subsidiary level.